stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Free cash flow
Ligand Pharmaceuticals Incorporated's free cash flow for fiscal 2025 was $48.3M, down 43.1% from $84.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $79.8M. Over the past ten years it has ranged from −$31.9M (fiscal 2019) to $183.2M (fiscal 2018); the current reading is higher than 45% of that period. Ligand Pharmaceuticals Incorporated ranks 33rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $48.3M | (43.06%) |
| FY2024 | $84.8M | — |
| FY2023 | −$3.9M | — |
| FY2022 | $120.0M | 70.16% |
| FY2021 | $70.5M | 36.99% |
| FY2020 | $51.5M | — |
| FY2019 | −$31.9M | — |
| FY2018 | $183.2M | 95.97% |
| FY2017 | $93.5M | 126.93% |
| FY2016 | $41.2M | 9.53% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$25.1M | — |
| Jun 2026 | $23.9M | (56.94%) |
| Mar 2026 | $55.4M | 22.38% |
| Dec 2025 | $45.3M | 204.14% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement